Liquid Biopsy & MRD
Natera names Solomon Moshkevich CEO
The 15-year insider who led Natera into oncology takes over from Steve Chapman. Same day: Q3 revenue up 34.1% and 2026 guidance raised by $140M at the midpoint.
Read the full story →Guardant's Shield more than triples volume
83,000 screening tests in Q3, commercial coverage above 80% of eligible lives, and total revenue up 36% to $361.0M. Guidance raised again.
Read the full story →Earnings & Strategy
Tempus grows revenue 23% to $411.5M
MRD volume up 300%, data licensing bookings past $550M this year, and the Personalis deal through regulatory review.
Read the full story →Myriad raises its guidance midpoint
Revenue flat at $202.7M as Myriad gets ready to hand its prenatal tests to Labcorp for $210M and focus on cancer care.
Read the full story →Research Tools
10x Genomics starts shipping Atera
Revenue up 1% but gross margin up to 75%, guidance raised, and a new cloud analysis platform, Sentira, powered by NVIDIA computing and Anthropic’s Claude.
Read the full story →Talent Insight
Monitoring and screening are rewriting the org chart
- MRD volumes are climbing fast, which makes oncology reps, MSLs and lab operations people who know tumour-informed monitoring the profiles to watch.
- Blood-based screening sells like primary care, not specialist oncology. People who've sold screening to health systems and payers are a different, and scarcer, profile.
- New CEOs and portfolio sales tend to reshuffle the layer below. Expect commercial leadership movement across the sector into early 2027.
Building a team in Genomics & Diagnostics?
Eric Sharma specialises in Genomics & Diagnostics hiring at QP Group. Talk to Eric about the market, salaries or a search.
